Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863076 | 0.93 | MEN1 (0.52) | MEN1POLBKMT2ACA2TDP1 | |
| SCHEMBL5863183 | 0.90 | MAPT (0.53) | MEN1POLBKMT2ATDP1L3MBTL1 | |
| SCHEMBL5863106 | 0.89 | TDP1 (0.52) | MEN1POLBKMT2ACA2TDP1 | |
| SCHEMBL5863173 | 0.87 | MRGPRX4 (0.53) | KMT2A | |
| SCHEMBL5863152 | 0.84 | CA2 (0.54) | POLBCA2NPC1RAB9A | |
| SCHEMBL5863066 | 0.84 | MEN1 (0.50) | MEN1POLBKMT2ATDP1L3MBTL1 | |
| SCHEMBL5638993 | 0.81 | SMN1; SMN2 (0.57) | MEN1POLBKMT2ANPC1RAB9A | |
| SCHEMBL5863181 | 0.81 | SMN1; SMN2 (0.47) | MEN1KMT2ATDP1L3MBTL1NPC1 | |
| SCHEMBL2404818 | 0.79 | NPC1 (0.59) | POLBNPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL5863189 | 0.78 | NR4A2 (0.57) | KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | MEN1 705/4885POLB 4500/4885KMT2A 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.